AMIX News & Events

Autonomix announced the development of a proprietary standalone neural sensing platform following preclinical results showing evidence of the ability to identify renal neural activity and detect real-time changes in neural activity following intervention. The standalone neural sensing platform will be built on the same core sensing technology as Autonomix's lead pancreatic cancer pain program and is being developed in parallel with that initiative, enabling a capital-efficient expansion into cardiology, which represents a significant new therapeutic market opportunity. In recent preclinical studies, changes in blood pressure were induced and reproducible changes were observed in recorded neural signals in real time. Additional studies are underway to further characterize the relationship between these signals and sympathetic nerve activity. These findings highlight the potential for a more precise, feedback-driven or closed-loop approach to renal denervation and may address a longstanding challenge in the field, where the absence of direct physiological feedback can contribute to variability in treatment outcomes.

Autonomix announced the United States Patent and Trademark Office has issued U.S. Patent No. 12,544,131. The newly granted patent covers catheter-based transvascular tools and systems designed to operate from within a bodily lumen, where deployable probes penetrate into and/or through a lumen wall to access tissue and nerves located outside the vessel. The patent includes claims relating to multi-site electrophysiological sensing, incorporating sensing at a target site, secondary site, and reference site to improve signal quality and procedural confidence. It also encompasses methods for assessing procedural completion based on electrophysiological signal processing, including detection of changes in neural activity patterns to assess treatment effect and procedural outcomes.